View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 26, 2020updated 12 Jul 2022 11:39am

Trialbee and Clinerion partner for expanded access to global RWD

Patient recruitment firm Trialbee has announced that it has partnered with medical data informatics company Clinerion.

Patient recruitment firm Trialbee has announced that it has partnered with medical data informatics company Clinerion.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

This partnership is aimed at ‘accelerating time’ to market by reducing timelines of patient recruitment and enrolment.

It also seeks to reduce costs associated with ‘patient recruitment’ and ‘loss-to-follow-up’.

Trialbee CEO Lollo Eriksson said: “This partnership significantly broadens our global reach and allows us to expand our data set for predictable intelligence-based patient recruitment and retention to support traditional and decentralised trials.

“This is a great opportunity for both organisations to make trials simpler for investigators and to deliver on our commitment of expediting clinical research by optimising the use of real-world data.”

Because of limited access to patients matching with the study criteria, over 80% of clinical trials are being delayed and about 30% of sites never enrol patients.

Clinerion’s expertise in leveraging real-world electronic health record (EHR) data for clinical research combined with Trialbee’s multiple step qualification process is expected to significantly streamline this process.

Trialbee said that its platform provides ‘full transparency’ of the status of the referred patient flow across the entire trial.

This platform offers sites and sponsors with full insight into the recruitment strategies’ effectiveness.

Clinerion CEO Rentsch said: “Patients are at the centre of everything Clinerion does, and this partnership will ensure better outcomes for patients.

“Together, we will be able to match more of the right patients to the leading-edge trials that can bring them the care they need, and, ultimately, our improvement of the efficiency of recruitment for clinical trials will accelerate the introduction of new medicines and interventions.”

Switzerland-based Clinerion claims to speed up clinical research and medical access to treatments for patients by generating real-world data from its global network of partner hospitals for Real World Evidence analyses.

In June this year, Trialbee partnered with Datavant to power patient-centric clinical trial recruitment and engagement.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena